ERBB2 and breast cancer: Using T-DM1 response data in advanced HER2+ BC (i.e., PR and CR vs. stable disease [SD] and progression of disease [PD]), an optimized ERBB2 mRNA cutoff was identified based on Fisher’s exact test.